
Twenty patients with rheumatic heart valve disease undergoing valve replacement were randomly divided into 2 group (n = 10): phosphocratine (neoton) group (group CP) in which 4.0 g neoton was used intravenously 2 days before operation and control group (group C) in which 5% G. S instead of neoton. The results showed that spontaneous recovery rate of heart beat in group CP was significantly higher than that in group C; requirement of inotropic drugs, serum MDA value and ultrastructural changes of myocardium were less in group CP than those in group C. There were no differences in release of myocardial enzymes and myocardial ATP content between 2 groups. It is suggested that neoton is an effective cardioprotective drug.
Heart Valve Prosthesis Implantation, Cardiopulmonary Bypass, Cardiotonic Agents, Phosphocreatine, Superoxide Dismutase, Myocardium, Rheumatic Heart Disease, Humans
Heart Valve Prosthesis Implantation, Cardiopulmonary Bypass, Cardiotonic Agents, Phosphocreatine, Superoxide Dismutase, Myocardium, Rheumatic Heart Disease, Humans
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
